Barbara W. Trautner, 1 Baylor Plaza, BCM286, Houston, TX 77030, USA. E-mail: firstname.lastname@example.org
We hypothesized that pretreating urinary catheters with benign Escherichia coli HU2117 plus an antipseudomonal bacteriophage (ΦE2005-A) would prevent Pseudomonas aeruginosa biofilm formation on catheters – a pivotal event in the pathogenesis of catheter-associated urinary tract infection (CAUTI).
Methods and Results
Silicone catheter segments were exposed to one of four pretreatments (sterile media; E. coli alone; phage alone; E. coli plus phage), inoculated with P. aeruginosa and then incubated up to 72 h in human urine before rinsing and sonicating to recover adherent bacteria. Pseudomonas aeruginosa adherence to catheters was almost 4 log10 units lower when pretreated with E. coli plus phage compared to no pretreatment (P < 0·001) in 24-h experiments and more than 3 log10 units lower in 72-h experiments (P < 0·05). Neither E. coli nor phage alone generated significant decreases.
The combination of phages with a pre-established biofilm of E. coli HU2117 was synergistic in preventing catheter colonization by P. aeruginosa.
Significance and Impact of the Study
We describe a synergistic protection against colonization of urinary catheters by a common uropathogen. Escherichia coli-coated catheters are in clinical trials; adding phage may offer additional benefit.
Catheter-associated urinary tract infection (CAUTI), one of the most common hospital-associated infections, is increasingly caused by highly resistant gram-negative organisms (Hidron et al. 2008). Pseudomonas aeruginosa is an important cause of CAUTI and is also one of the most problematic multidrug-resistant (MDR) gram-negative pathogens (McGowan 2006; Giamarellou and Poulakou 2009). Many strains of P. aeruginosa are resistant to all commonly used antimicrobial agents (McGowan 2006), so there is a critical need for novel approaches to suppress the growth of this pathogen in the bladder. In the numerous patients who have a legitimate requirement for long-term urinary catheter use, no strategy is truly effective at preventing bladder invasion by urinary pathogens (Trautner et al. 2005).
CAUTI is also a biofilm-related infection, which contributes to the low efficacy of standard antimicrobial therapy (Maki and Tambyah 2001; Donlan and Costerton 2002). Organisms in biofilms are not consistently eradicated by the same therapeutically achievable levels of antimicrobial agents to which their planktonic counterparts are susceptible, and biofilms may provide a niche for antimicrobial-resistant organisms (Donlan and Costerton 2002). Eradication of pathogenic organisms from a urinary tract with ongoing catheterization is nearly impossible; antibiotic use leads to temporary suppression followed by emergence of resistant strains (Maki and Tambyah 2001).
Our bacterial interference approach to CAUTI treatment and prevention exploits the tenacity of biofilms by utilizing urinary catheters coated with a biofilm of Escherichia coli HU2117 (a derivative of E. coli 83972) to colonize the catheter and bladder with this benign and potentially protective strain (Trautner et al. 2007; Prasad et al. 2009). Our previous in vitro work with E. coli HU2117-coated catheters supports a potential role for this organism in preventing recurrent CAUTI against such diverse organisms as enterococci, Candida, Providencia and pathogenic E. coli (Trautner et al. 2002, 2003, 2007, 2008; Prasad et al. 2009). However, in clinical trials, some biofilm-forming organisms, notably P. aeruginosa, overgrew the E. coli HU2117 on urinary catheters (Trautner et al. 2007; Prasad et al. 2009). Here, we explore the potential of lytic bacteriophages (‘phages’) to improve the persistence of the benign E. coli on the catheter and in the bladder. The difficulty of eradicating biofilm infections from medical devices has prompted studies of the use of lytic phages for this application (Donlan 2009). Phages are viruses that are highly specific to one or a few related target bacterial species; they are self-replicating in the presence of host cells and self-limiting in their absence; phages are frequently effective against multidrug-resistant organisms because they kill cells by different molecular mechanisms; they cannot infect eukaryotic cells and can be selected so as not to infect normal, beneficial microflora.
Many bacteriophages are known to exhibit narrow host range, and their host bacteria will develop resistance (Lenski and Levin 1985; Mizoguchi et al. 2003), making total eradication of the target species unlikely. However, our goal is not to eradicate the pathogenic species (P. aeruginosa), but rather to shift the ecological balance of the urinary tract early on, such that growth of the benign biofilm is favoured over growth of uropathogens. Emergence of phage-resistant populations in co-evolving host-phage systems takes some time and can be slowed through the use of phage mixtures (Lenski and Levin 1985; Maki and Tambyah 2001; McGowan 2006; Labrie et al. 2010). Additionally, in P. aeruginosa, phage resistance often arises through modification of bacterial surface structures whose loss reduces bacterial virulence, such as the type IV pili necessary for biofilm formation by P. aeruginosa (Chibeu et al. 2009; Labrie et al. 2010). Thus, development of phage resistance may come at the cost of biofilm-forming ability.
We explored the following hypotheses: (i) pretreating urinary catheters with benign E. coli HU2117 plus an antipseudomonal phage will prevent pathogen colonization of the catheter surface when challenged with P. aeruginosa in the host range of the phage, (ii) phage-resistant variants of P. aeruginosa arising during these bacterial interference experiments will have diminished virulence in terms of either growth rate or catheter adherence. Our experimental design modelled an ‘at the bedside’ treatment approach in which a cocktail of phages targeting pre-existing bladder populations of uropathogenic species would be added to the bladder at the time of insertion of a urinary catheter coated with benign E. coli HU2117.
Materials and methods
Organisms and culture conditions
Escherichia coli HU2117 is a derivative of E. coli 83972, which was originally isolated in a 12-year-old Swedish girl who carried it asymptomatically in her bladder (Andersson et al. 1991). Escherichia coli HU2117 has a deletion in papG and thus cannot express functional P-fimbriae, associated with pyelonephritis (Hull et al. 2002). Our challenge pathogen was P. aeruginosa EAMS2005-A, a clinical isolate from the Centers for Disease Control and Prevention (CDC) Clinical and Environmental Microbiology Branch culture collection. This organism was the host for phage ΦE2005-A, which was collected from the Snapfinger Creek Wastewater Treatment Plant in Dekalb County, Georgia, as previously described (Fu et al. 2010). Bacterial stocks were stored in Luria broth (LB) plus 10% glycerol at −80°C and propagated on Trypticase Soy Agar (TSA) plates (BBL™ Trypticase™ Soy Agar, BD211043; Becton, Dickinson & Co., Franklin Lakes, NJ) at 37°C, as needed. Escherichia coli and P. aeruginosa were separately subcultured first on solid media (TSA), then in LB broth overnight (rocking, 37°C). This overnight liquid culture was diluted to an optical density at 600 nm (OD600) of 0·2–0·3 (approximately 108 organisms per ml) prior to use. Phage ΦE2005-A was propagated using the soft agar overlay method and stored at 4°C, shielded from light (Adams 1959). Human urine was collected from one female donor, sterilized by filtration (0·22 μm) and stored in large-volume batches at 4°C until needed. We chose to work in real urine as our prior bacterial interference studies have all been carried out in human urine, both in vitro and in vivo.
Phage susceptibility of clinical Pseudomonas aeruginosa isolates
We determined the susceptibility of 18 clinical isolates of urinary P. aeruginosa to the six phages in our library to choose a phage for the bacterial interference experiments. Lytic assays were performed using the spot test method (Kutter and Sulakvelidze 2005). Briefly, bacterial lawns of each P. aeruginosa strain were seeded in soft agar that was allowed to solidify for at least 5 min; 15-μl droplets of phage suspensions (at approximately 108 PFU ml−1) were placed on the agar and allowed to air dry for 30 min. Plates were incubated overnight, and each phage zone of lysis was graded on a 0–4 scale of opaque (0, no lysis) to clear (4, total lysis).
Experimental set up and protocol
Twenty four-hour exposure experiments
All silicone urinary catheters (Bardex Uncoated Silicone Foley Catheters, Bard Medical Division, Covington, GA, USA, Cat. no. 165812) were each sliced into four segments (approximately 6 cm each) using sterile technique. Each catheter segment underwent one of four pretreatment conditions in an individual tube of 50 ml LB broth (Fig. 1) prior to exposure to the challenge pathogen. Specifically, in step 1, catheter segments were aseptically transferred to tubes containing one of the following: (i) sterile media (control); (ii) 105E. coli colony-forming units (CFU) ml−1; (iii) 108 PFU ml−1 phage ΦE2005-A; (iv) 105E. coli CFU ml−1 plus 108 PFU ml−1 phage ΦE2005-A. After a 24-h incubation at 37°C with rocking, each catheter segment was transferred into a fresh tube of LB broth and inoculated with P. aeruginosa at a concentration of 105 CFU ml−1 for a 30-min incubation at 37°C with rocking. Catheter segments were then moved to fresh tubes of filter-sterilized human urine for the final 24-h incubation at 37°C with rocking. Catheters were harvested by immersing each 6-cm catheter segment in three different tubes of 50 ml phosphate-buffered saline (PBS), followed by flushing the inner catheter lumen with 30 ml PBS. Each segment was then aseptically cut into three 1-cm subsegments; each subsegment was placed into a tube containing 1 ml of PBS plus 0·01% sodium dodecyl sulfate (SDS) and was sonicated for 10 min. at 50 Hz. The sonicated fluid was plated onto selective media (TSA and LB agar plus 100 μg ml−1 ampicillin; the LB plus ampicillin media selected for P. aeruginosa, which is innately resistant to ampicillin, while prohibiting growth of E. coli HU2117) and incubated overnight to quantify the numbers of adherent P. aeruginosa and E. coli (Trautner et al. 2002, 2003). The detection limit for this method was 1 CFU per 1-cm catheter segment sample. Planktonic bacteria were quantified by plating dilutions of incubated urine on the same types of selective media (TSA and LB agar plus 100 μg ml−1 ampicillin) and incubating overnight. At each step in the protocol, plaque assays were performed using the soft agar overlay method to enumerate phage titres (Kutter and Sulakvelidze 2005).
Extended time course experiments: 24-, 48-, and 72-h exposures
To investigate how the phage-enhanced interference effect would function over a longer duration of time, the interference experiments were extended to 72 h, with daily movement of catheters to fresh filter-sterilized urine. In these experiments, three (rather than one) catheter segments were placed in each 50-ml tube at the start of each experiment. At the 24-h and 48-h time points, one catheter segment was removed for processing as previously described, while the remaining catheter segment(s) were transferred to a fresh 50-ml tube of urine and incubated further.
Viable counts from catheter subsegments and from spent media were log-transformed using the following algorithm: log10 [raw data + 1]. This transformation normalized the data and avoided the undefined function log10 0. For each catheter segment in each tube, the mean of the three 1-cm catheter subsections was taken as the representative value for that catheter in that particular experiment. All experiments were repeated at least four times. Analyses of variance (anovas) were conducted to compare the mean numbers of P. aeruginosa adherent to catheters or recovered from the urine under the four pretreatment conditions, followed by the appropriate post hoc comparison tests (Holm–Sidak method for comparisons to the ‘no pretreatment’ control or Dunn's method for all pairwise comparisons). The correlation between adherent and planktonic P. aeruginosa was determined using the Pearson correlation test. Numbers of E. coli adherent to, or in the urine surrounding, phage-treated vs untreated catheters were compared by t-tests. Statistical comparisons were performed using sigmaplot ver. 11.0 software (Systat Software, Inc., San Jose, CA, USA).
Characterization of potentially phage-resistant variants of Pseudomonas aeruginosa
Pseudomonas aeruginosa isolates recovered from catheters or from urine after 24 or more hours of exposure to ΦE2005-A were subcultured onto TSA before storing at −80°C in LB with 10% glycerol. These variants were tested for oxidase activity, for ability to grow on MacConkey agar (Becton, Dickinson & Co.) and LB agar (Lennox L Agar; Invitrogen, Carlsbad, CA) with 100 μg ml−1 of ampicillin and for ability to produce distinct colony morphology and pigments on Cetrimide agar (EMD Chemicals, Gibbstown, NJ, USA). Strains that were oxidase positive and grew on both MacConkey and LB agars and produced colony morphology characteristic of P. aeruginosa on Cetrimide agar were identified using the Vitek II automated identification system (BioMérieux, Durham, NC, USA).
We also characterized the susceptibility of potentially phage ΦE2005-A-resistant variants of P. aeruginosa to seven antipseudomonal phages (ΦE2005-A, ΦPaer4, ΦW2005-B, ΦE2005-C, ΦPaer14 and ΦM4) (Table 1). Lytic assays were performed using the spot test method as earlier (Kutter and Sulakvelidze 2005). Each phage zone of lysis was graded on a 0–4 scale of opaque (0, no lysis) to clear (4, total lysis).
Table 1. Characteristics of six antipseudomonal phages used in this study
CDC, Centers for Disease Control and Prevention.
Phage and bacterial host strains received from the CDC originated in the collections of the Biofilm Laboratory in the Clinical and Environmental Microbiology Branch, CDC, Atlanta, Georgia.
Standard growth curve assay of all potentially phage ΦE2005-A-resistant P. aeruginosa variants and the parent strain P. aeruginosa EAMS2005-A was carried out in filter-sterilized human urine: growth curve media was sampled for plate counts every hour for 8 h and again at 24 h. Doubling times of four repetitions per isolate were compared to the parent strain of P. aeruginosa using the Wilcoxon rank-sum test.
Catheter biofilm formation assay
Two of the slowest-growing and two of the fastest-growing experimental variants (as determined by length of doubling time) were tested alongside parent strain P. aeruginosa EAMS2005-A for biofilm formation on non-pretreated catheters through overnight incubation in filter-sterilized human urine. Using the biofilm growth protocol already described, at least three repetitions were completed for each variant, with data analysis as per the interference experiments above.
Phage host range in clinical P. aeruginosa isolates
We chose phage ΦE2005-A for our bacterial interference protocol because ΦE2005-A lysed over 50% of the clinical P. aeruginosa isolates tested and made clear, well-demarcated plaques, while its host P. aeruginosa also had distinct colonies on agar plates.
Interference experiments: after a 24-h exposure
The E. coli plus phage combination was the only pretreatment condition that had a significant effect on the adherence of P. aeruginosa (P < 0·001, anova followed by Holm-Sidak) (Fig. 2). Pseudomonas aeruginosa adherence to catheters was almost 4 log10 units lower following pretreatment with E. coli plus phage (0·90 log10 CFU cm−1), in comparison with no pretreatment (4·73 log10 CFU cm−1). In several experiments, no P. aeruginosa was recovered from catheters that had been pretreated with E. coli plus phage. The numbers of E. coli on catheters was not significantly affected by the presence of phage in the media (P = 0·4, t-test).
Extended time course experiments: after exposure for 24, 48, and 72 h
In extended time course experiments, the mean number of P. aeruginosa isolated from E. coli plus phage-pretreated catheters was more than 3 log10 units lower than that collected from untreated catheters at 24 h (1·2 log10vs 4·3 log10 CFU cm−1), 48 h (0·5 log10vs 5·3 log10 CFU cm−1) and 72 h (1·6 log10vs 6·1 log10 CFU cm−1) (P < 0·05 for all, anova, followed by Dunn's Test) (Fig. 3a). The reduction ranged from 3·6- to 11·7-fold. Averages of adherent P. aeruginosa per pretreatment condition differed significantly at 24-, 48- and 72-h time points (anova, P = 0·004, P < 0·001, P < 0·001, respectively), with the significance arising from the comparison of the E. coli plus phage pretreatment to the control condition (no pretreatment). Of note, in the control condition, the numbers of catheter-adherent P. aeruginosa increased 1·8 log10 units over time from 24 to 72 h (4·3 log10 CFU cm−1vs 6·1 log10 CFU cm−1, P = 0·03, Mann–Whitney U-Statistic). No such increase was seen for P. aeruginosa on E. coli-alone-pretreated catheters (4·6 log10vs 5·1 log10 CFU cm−1, P = 0·29, t-test). However, at 72 h, the differences between catheter-adherent P. aeruginosa in the control and E. coli pretreatment groups did not differ significantly (6·1 log10vs 5·2 log10 CFU cm−1 respectively, P = 0·08, t-test). Overall, neither the E. coli-alone nor the phage-alone pretreatment produced any significant reductions in P. aeruginosa recovery from catheters when compared to control catheters at any time point.
For several replicates, catheter-associated P. aeruginosa were not detected at all for the E. coli plus phage-treated catheters. Pooling results from all tubes that contained phage in all experimental replicates, we found that P. aeruginosa was completely eradicated from catheters in eight of 27 (30%) experiments in which catheters had been pretreated with E. coli plus phage, in contrast to zero of 14 (0%) experiments in which catheters had not been pretreated with E. coli plus phage (P = 0·02, Fisher's exact test). Again, the number of E. coli collected from E. coli-only-pretreated catheters did not differ significantly from that recovered from E. coli plus phage-pretreated catheters at 24, 48 or 72 h (t-test, P = 0·074, P = 0·268, P = 0·252, respectively) (Fig. 3b). Escherichia coli biofilm on E. coli-only-pretreated catheters increased by approximately 1 log10 over time, from 4·6 log10 at 24 h to 5·6 log10 at 72 h (P = 0·04, t-test). The number of biofilm-associated P. aeruginosa correlated positively with the number of planktonic P. aeruginosa for all three time points (Pearson Correlation, P ≪ 0·001) (Fig. 3c).
Characterization of phage-resistant experimental variants
Thirteen potentially phage-resistant isolates of P. aeruginosa EAMS2005-A (recovered from phage-treated catheters) were subcultured and stored for further characterization. Many of these variants resembled their parent strain in colony morphology but were collected because they had grown in a tube that contained the phage and thus could have become resistant to that phage. Other isolates demonstrated considerable variety in terms of colony shape, size and colour. All variants were identified as P. aeruginosa.
Phage susceptibility of experimental Pseudomonas aeruginosa isolates
The average lytic score for the thirteen potentially phage-resistant variants of P. aeruginosa EAMS2005-A when tested with ΦE2005-A was 1·4, in contrast to the lytic score of 4 for the parent strain (completely clear plaques). Two variants were fully resistant to ΦE2005-A, three showed barely any clearing in plaques, and one remained fully susceptible to ΦE2005-A. The other seven variants displayed diminished susceptibility to ΦE2005-A in the form of semi-opaque plaques.
The doubling time of the parent strain P. aeruginosa EAMS2005-A was 33 ± 7 min, while the average doubling time of experimental variants was 40 ± 10 min (P = 0·27, Wilcoxon rank-sum test) (Fig. 4).
The two slowest-growing (100909nF and 101127nE) and two of the faster-growing experimental variants (100806nE and 101029bF) were compared with the parent strain for ability to form biofilms on urinary catheters after overnight incubation in filter-sterilized human urine. Mean doubling times of these four variants were as follows (four repetitions): 49 min for 100909nF, 52 min for 101127nE, 35 min for 100806nE and 39 min for 1010029bF. Significantly fewer catheter-adherent organisms were recovered from slow growers 100909nF and 101127nE than from the parent P. aeruginosa (3·38 log10 and 3·13 log10, respectively, vs 4·8 log10 CFU cm−1 for the parent strain), (P < 0·05 for both comparisons to the parent strain using anova followed by Holm–Sidak); fast growers 100806nE and 101029bF did not have significantly reduced biofilm formation compared to the parent strain (Fig. 5).
In our previous in vitro bacterial interference studies, we found that E. coli 83972 (the parent strain for HU2117) itself was able to significantly impede catheter colonization by the following pathogens: uropathogenic E. coli, Candida albicans, Enterococcus faecalis and Providencia stuartii (Trautner et al. 2002, 2003). However, we did not challenge the E. coli-coated catheters in vitro with P. aeruginosa in those studies, and in vivo, we found that this aggressive biofilm-forming organism could overgrow the E. coli HU2117 (Trautner and Darouiche 2002; Prasad et al. 2009). The results of our current study imply that the combination of E. coli HU2117 and antipseudomonal phage could be effective at preventing catheter colonization by P. aeruginosa.
Our results demonstrate that E. coli HU2117 and phage ΦE2005-A had a strongly synergistic effect on preventing urinary catheter colonization by P. aeruginosa, both in overnight experiments and when the pathogen exposure time was lengthened to 72 h. Pseudomonas aeruginosa colonization of catheters was completely prevented in 30% of experiments in which the phage plus E. coli combination was used. In those experiments where colonization was not completely prevented, P. aeruginosa populations were several orders of magnitude lower than in all other treatments. Only the combination treatment significantly reduced P. aeruginosa biofilm formation. This is the first report of a synergistic effect of bacteriophage and a probiotic bacterium on prevention of pathogenic biofilm formation.
Consistent with the observations that motivated this study, E. coli HU2117 alone did not prevent catheter colonization by P. aeruginosa. However, E. coli HU2117 alone did have some interference effect on P. aeruginosa, preventing the biofilm of this organism from increasing between 24 and 72 h (in contrast to the untreated catheters).The inability of the phage-only treatment to prevent P. aeruginosa growth on the catheter was unexpected though, because Fu et al. found that phage alone could significantly decrease catheter adherence by P. aeruginosa by over 2 logs in a flowing model using diluted tryptic soy broth (Fu et al. 2010). The difference may be related to the presence of a hydrogel coating, which enabled adsorption of the phages or the use of a phage cocktail in the Fu et al. studies. Fu et al. hypothesized that phages were associating with the hydrogel coating on the catheters used in that study, whereas the current work used uncoated silicone catheters. In several instances, the E. coli HU2117 biofilm increased by more than 1 log over 72 h of incubation, as we observed in human studies (Prasad et al. 2009). Unsurprisingly, the presence of antipseudomonal phage did not substantially affect E. coli HU2117 population sizes.
The results of the present study support our original hypothesis that the combination of phage and bacterial interference will reduce biofilm formation by P. aeruginosa on urinary catheters to a significantly greater extent than either phage treatment or treatment by bacterial interference alone. Phage alone was clearly insufficient to kill all P. aeruginosa cells prior to mixed biofilm formation on the catheter, and similarly, E. coli was unable to out-compete P. aeruginosa during biofilm formation. It is likely that in the combination E. coli plus phage pretreatment, the phage reduced the initial P. aeruginosa population sufficiently to allow the E. coli biofilm to become further established. As a consequence, a mixed biofilm does not appear to have formed, or when it did, the only P. aeruginosa cells recovered were phage-resistant mutants, and those in low numbers. This suggests that if the initial P. aeruginosa population is held in check, the E. coli biofilm can develop and mitigate biofilm formation by P. aeruginosa, possibly due to reduced competitive ability of the phage-resistant mutants. The observed correlation between numbers of P. aeruginosa on catheters and in urine supports this numbers-based theory, as the correlation probably results from a cyclical seeding process from catheter to urine and back. Harcombe and Bull found that addition of a phage specific for E. coli in an E. coli/Salmonella enterica planktonic community resulted in a significant reduction in its host strain even though E. coli densities with phage present reached high levels in the absence of S. enterica (Harcombe and Bull 2005). Kay et al. (2011) also observed a similar effect on P. aeruginosa in a P. aeruginosa/E. coli culture in the presence of a P. aeruginosa-specific phage. Both of these studies suggest that the combined effect of lytic phage infection and microbial competition can result in the predominance of one species in the biofilm, as observed in the present study.
Fu et al. (2010) addressed the issue of the rapid emergence of phage-resistant variants of P. aeruginosa by pretreating urinary catheters with a phage cocktail. We found that adding E. coli HU2117 to the catheter pretreatment is a highly effective alternative approach, because in 30% of the experiments in which both E. coli and phage had been applied, no P. aeruginosa was found on the catheter. A promising future direction for our interference studies will be to combine a cocktail of multiple phages with the E. coli-coated catheters, taking advantage of two approaches to maximize the pathogen suppression.
Despite the large reduction in P. aeruginosa growth following E. coli plus phage pretreatment, we did still observe frequent emergence of phage-resistant variants of P. aeruginosa in that context. Although the absolute doubling times of phage-resistant isolates of P. aeruginosa were all longer than for the parent strain, the wide standard deviations precluded finding a significant difference in growth rates. Nevertheless, the finding that slower-growing phage-resistant variants of P. aeruginosa had reduced virulence in terms of catheter adherence is a finding with potential clinical relevance and is in accord with several other recent studies of the effect of phage exposure upon bacterial virulence. Phage resistance often arises through modification of bacterial surface structures (Labrie et al. 2010). Type IV pili and their associated twitching motility are essential for biofilm formation by P. aeruginosa (O'toole and Kolter 1998). In Chibeu et al.'s (2009) studies of another P. aeruginosa-phage pair, P. aeruginosa PAO1 and ФKMV, the loss of type IV pili conferred resistance to phage ФKMV but also resulted in diminished twitching motility. A mouse study of phage therapy for Salmonella enterica found a similar association of the acquisition of phage resistance with the loss of virulence (Capparelli et al. 2010). In our interference experiments, our goal is not to eradicate the pathogenic species, but rather to shift the ecological balance so that the benign E. coli can persist and protect the catheter and the bladder. Virulence modification in terms of biofilm formation suits this purpose very well.
In summary, pretreating urinary catheters with a benign E. coli biofilm in addition to antipseudomonal phages inhibits colonization by P. aeruginosa more effectively than either the E. coli biofilm or the phage pretreatment alone. This synergistic effect is promising when considering the application of this system in a clinical setting, where the phage may reinforce the ability of our benign E. coli biofilm to prevent uropathogen adherence and colonization.
BWT's work was supported by the National Institutes of Health HD058985 and a VA Career Development Award from Rehabilitation Research & Development B4623; also with some use of resources and facilities at the Houston VA HSR&D Center of Excellence (HFP90-020) at the Michael E. DeBakey VA. SML was partially supported by the American Society for Microbiology/Center for Disease Control and Prevention International Postdoctoral Fellowship. We appreciate the assistance of Megan Burger and Lisa Atkins in the interference experiments and in testing the variant strains of P. aeruginosa, respectively. We acknowledge Elizabeth Perez and Bette Jensen of CDC for assistance. This work was performed through a Research Collaboration Agreement between Baylor College of Medicine and the CDC.
Conflict of Interests
The authors do not have any financial or other associations that might pose a conflict of interest.